@entity195 ( @entity195 ) has rarely been reported in association with @entity5 . In most cases the autoimmune nature of the disease itself or immunosuppressive drug use has been blamed for malignant transformation. We report 13 cases of @entity195 concurrent with @entity5 as well as treatment-related morbidities in this particular @entity1 group. Between 1986 and 1999, 400 @entity1 were diagnosed as having @entity195 in Hacettepe University Hospitals. Of these 13 @entity1 , 3.25% developed @entity5 within a median follow-up time of 9.8 years. @entity5 were diagnosed in 10 @entity1 and haematological or @entity706 in three. Surgery was performed in seven @entity1 , whereas radiotherapy was applied in six and chemotherapy in eight. A literature review revealed 27 cases of @entity195 associated with @entity5 , mostly lymphoid or haematological. Ten of our cases were @entity5 , and to our knowledge most of these are the first reported cases of specific @entity5 concurrent with @entity195 . Treatment-related morbidities were wound infection as surgical morbidity in one @entity1 (1/7) and radiotherapy-related morbidity in three (3/6) @entity1 in a median follow-up time of 2 years. @entity5 in addition to lymphoid and haematological @entity5 are also seen during the course of @entity195 . Radiation therapy may cause severe late @entity137 in the presence of @entity195 . Chemotherapy and surgery are fairly safe for the treatment of @entity5 in @entity195 @entity1 .

Malignancy in XXXX : a report of 13 cases and a review of the literature.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoid malignancies'] @entity5 :: ('MESH:D009369', 'Disease') :: ['solid tumors', 'neoplastic disease', 'Solid tumors', 'malignant diseases', 'malignancies'] @entity195 :: ('MESH:D000544', 'Disease') :: ["Beh  et's disease", 'BD']
@entity195 :: (MESH:D000544,Disease) :: ['Beh  et's disease']
